ET patients with JAK2V617F mutation presented with higher hemoglobin (Hb) and hematocrit (Hct) levels and lower platelet count at diagnosis compared to patients without mutation (p=0.001, p=0.001, and p=0.043, respectively). The gene discussed is GSTM1; the disease is essential thrombocythemia.